Respiratory depression produced by intravenously administered NBQX.

To determine whether blockade of non-N-methyl-D-aspartate (non-NMDA) excitatory amino acid receptors affects breathing, we administered the non-NMDA receptor antagonist, 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX), to anesthetized cats while monitoring phrenic nerve discharge, blood pressure and heart rate. NBQX, 3 and 10 mg/kg, i.v., reduced phrenic amplitude 59 +/- 20% (n = 3) and 88 +/- 6% (n = 5), respectively, and decreased respiratory rate. Phrenic activity was completely silenced in 3 animals. These effects were accompanied by decreased blood pressure and heart rate. Our data indicate that NBQX, a competitive antagonist of non-NMDA receptors, is a powerful depressant of cardiorespiratory activity.